Market requirements · FR
France
ANSM names compounds individually in its public alerts and has issued sanitary-police decisions against named companies. This is the most active enforcement posture found in the EU.
Buyers in this market search for: grossiste peptides, fournisseur peptides, peptides de recherche.
| Tell us the compounds you need for France. | Ask about France |
The regime
How compounds are classified in France
| Governing law | The Code de la sante publique, administered by ANSM. Public advertising of prescription medicines is prohibited. |
|---|---|
| The regulator's stated position | ANSM published a consumer alert, updated 22 July 2026, naming retatrutide, BP180, TB500, GH, GHK-Cu, BPC-157 and NAD+ as products sold illegally online. The alert states that a product marked 'For research use only', 'Reserve a la recherche' or 'Not for human use' must not be used by consumers, and reports hospitalisations linked to fraudulent retatrutide. |
| Named enforcement, one month apart | ANSM issued sanitary-police decisions against two named companies over products presented as containing GLP-1 agonists: one on 9 July 2026 and one on 16 July 2026. Both ordered product withdrawal and banned advertising. |
| Scale of the sweep | ANSM has stated it identified ten online merchant sites advertising products presented as GLP-1 agonists, laboratory-tested some, and found the declared active substance absent in cases. It says these medicines cannot be sold online even by an authorised pharmacy, and has strengthened customs controls with international partners. |
| Advertising | Because these compounds hold no marketing authorisation for the claims typically used to sell them, consumer-facing promotion in France is not restricted pharmaceutical advertising. It is advertising of an unauthorised product, which is a different and worse category. |
| Already supplying France? Send the compounds and volumes you buy today and we will quote against them. | Send your list |
Your obligations
What a buyer in France needs settled
- Read the ANSM alert before you order. It names compounds by name, and several of them are ordinary catalogue items elsewhere in Europe.
- Hold the French authorisation your intended activity requires.
- Keep all French-facing material entirely out of consumer-facing promotion.
- Take French counsel before supplying into the market. Of every market on this site, this is the one where we would say that most firmly.
We will ask about this at enquiry. We check the authorisations your activity requires before quoting, and we confirm the position per compound rather than for the market as a whole.
Sources
Check this yourself
Every position above traces to a dated public document. The authority, the document, the date and the link are below.
| Authority and document | Date | Link |
|---|---|---|
| ANSM Consumer alert naming compounds sold illegally online | updated 22 July 2026 | ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-u... |
| ANSM Sanitary-police decision, AZRL LTD, products presented as containing GLP-1 agonists | 16 July 2026 | ansm.sante.fr/actualites/decision-de-police-sanitaire-du-1... |
| ANSM Sanitary-police decision, Synedica Laboratories | 9 July 2026 | ansm.sante.fr/actualites/decision-de-police-sanitaire-du-0... |
Links go to the issuing body wherever one exists. Positions change. If you are relying on any of this, check the source rather than this page.
Market brief
Take the France brief as a PDF
The regime, the buyer obligations and all 3 sources, dated and linked, in one document you can forward.
Same region
Southern Europe
Buyers supplying one of these usually supply the others. The requirements are not the same.
| Code | Market | Sources | |
|---|---|---|---|
| IT | Italy | 1 sources | AIFA regulates under the Codice del farmaco and has warned on illegal GLP-1 su... |
| ES | Spain | 2 sources | AEMPS has issued a formal notice on illegal GLP-1 supply and directs buyers to... |
| PT | Portugal | 5 sources | INFARMED governs medicines under the Estatuto do Medicamento and has flagged a... |
| GR | Greece | 4 sources | EOF issued a public warning in July 2026, and related reporting names specific... |
Scope
How to use this page
A summary of the published regulatory position in France as at 2026-08-20, written for procurement teams deciding how to source. Every source is dated and linked so it can be checked at origin.
It is not legal advice. Full terms of supply, including where responsibility sits, are set out in our terms of supply.
Questions
Supplying into France
Do you supply into France?
We supply businesses that hold the authorisations their activity requires. Whether a specific compound can be supplied into France depends on that compound and on your authorisations, and we confirm it per compound at the enquiry stage.
Who carries the compliance obligation?
The importer of record and the party placing the product on the market, which is the buyer. We supply the batch documentation that supports your file. We cannot hold your authorisations for you.
How current is this page?
It was reviewed on 2026-08-20 and is scheduled for review again on 2026-11-18. Every source is dated and linked, so you can check the original.
We already supply into France. What changes if we source from you?
The batch documentation. You receive a Certificate of Analysis per batch, which can be issued under your own brand. The import and market-placing responsibilities stay where they are.
Is this legal advice?
No. It is a summary of the regulatory positions those authorities have published, as at the review date above. Take advice in your own market before you rely on it.
Enquire about supply into France
Tell us the compounds and your authorisations. We confirm per compound before anything ships.